IMBiologics Corp. (493280)

Overview

IMBiologics Corp. is a cutting-edge biopharmaceutical company dedicated to the research and development of innovative immunomodulatory antibody therapeutics. The company's mission revolves around restoring physiological homeostasis by precisely targeting essential immune system pathways. IMBiologics aims to address various autoimmune diseases, including but not limited to rheumatoid arthritis, hidradenitis suppurativa, Crohn's disease, and ulcerative colitis. Additionally, the company is working on immuno-oncology indications such as glioblastoma multiforme.

The focal point of IMBiologics’ research is its lead candidate, IMB-101, a bispecific antibody designed to inhibit key players like OX40L and TNFα, thereby regulating inflammatory cytokines and suppressing T-cell and plasma cell differentiation. By employing an array of proprietary platform technologies—such as IMBolution for multivalent antibody engineering, ePENDY for enhanced structural composition, and IM-OpDECon for optimizing antigen binding and antibody function—IMBiologics significantly accelerates the discovery and development processes for its expanding drug pipeline, which includes in-licensed candidates and multivalent antibody-drug conjugates.

Founded in 2020 and headquartered in Suwon-si, South Korea, IMBiologics is committed to forging global partnerships that facilitate the advancement of next-generation biologics for immunology and oncology applications. By engaging in licensing agreements with pharmaceutical partners, the company supports clinical advancement and commercialization efforts within international markets.

Products and Services

• IMB-101:

  This bispecific antibody serves as the lead therapeutic candidate of IMBiologics. IMB-101 targets OX40L and TNFα to modulate inflammatory responses, aiming to alleviate symptoms in patients with autoimmune diseases.

• IMBolution:

  This proprietary platform technology specializes in multivalent antibody engineering. It is utilized for enhancing the efficacy and therapeutic potential of antibody-based treatments.

• ePENDY:

  This technology focuses on the engineering of multivalent antibodies, ensuring optimal structural integrity and functionality for advanced therapeutic applications.

• IM-OpDECon:

  Designed for optimizing antigen binding, this platform method improves antibody function and physiochemical properties, enhancing the overall therapeutic profile of its products.

• Collaborative Model:

  IMBiologics operates on a collaborative business model, engaging in licensing agreements with pharmaceutical partners. This strategy allows for shared resources and expertise in advancing clinical programs and bringing therapies to market efficiently.

• Global Partnerships:

  The company actively seeks global collaborations to augment its research capabilities and enhance the commercialization prospects of its innovative therapies in international markets.